SEATTLE--(BUSINESS WIRE)--Calypso Medical Technologies, Inc., developer of GPS for the Body® technology used for the precise tracking of cancerous tumors during radiation therapy, today announced that 10,000 prostate cancer patients have had their radiation delivery safeguarded through the use of the Calypso® System. The 10,000th patient recently began treatment at Oregon Health & Science University’s (OHSU) Knight Cancer Institute.
